REGENERON PHARMACEUTICALS, INC. Acquisitions, Net of Cash Acquired
REGENERON PHARMACEUTICALS, INC. (REGN) reported Acquisitions, Net of Cash Acquired of $3.30 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-04.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired · last filed 2026-02-04
- REGENERON PHARMACEUTICALS, INC. payments to acquire businesses, net of cash acquired for the quarter ending 2025-12-31 was $300.00K, a 97.39% decline year-over-year.
- REGENERON PHARMACEUTICALS, INC. payments to acquire businesses, net of cash acquired for the quarter ending 2025-09-30 was $3.00M.
- REGENERON PHARMACEUTICALS, INC. payments to acquire businesses, net of cash acquired for the quarter ending 2024-12-31 was $11.50M, a 202.63% increase year-over-year.
- REGENERON PHARMACEUTICALS, INC. payments to acquire businesses, net of cash acquired for the quarter ending 2024-09-30 was $0.00, a 100.00% decline year-over-year.
- REGENERON PHARMACEUTICALS, INC. payments to acquire businesses, net of cash acquired for fiscal 2025 was $3.30M, a 80.00% decline from fiscal 2024.
- REGENERON PHARMACEUTICALS, INC. payments to acquire businesses, net of cash acquired for fiscal 2024 was $16.50M, a 69.95% decline from fiscal 2023.
- REGENERON PHARMACEUTICALS, INC. payments to acquire businesses, net of cash acquired for fiscal 2023 was $54.90M, a 76.16% decline from fiscal 2022.
- REGENERON PHARMACEUTICALS, INC. payments to acquire businesses, net of cash acquired for fiscal 2022 was $230.30M.
| Period end | Payments to Acquire Businesses, Net of Cash Acquired 3 month | Payments to Acquire Businesses, Net of Cash Acquired 6 month | Payments to Acquire Businesses, Net of Cash Acquired 9 month | Payments to Acquire Businesses, Net of Cash Acquired 12 month |
|---|---|---|---|---|
| 2025-12-31 | $300.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-04 | $3.30M derived: sum of 2 quarters · filed 2026-02-04 | $3.30M 10-K · filed 2026-02-04 | |
| 2025-09-30 | $3.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-28 | $3.00M 10-Q · filed 2025-10-28 | ||
| 2025-06-30 | $0.00 10-Q · filed 2025-08-01 | |||
| 2024-12-31 | $11.50M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-04 | $11.50M derived: sum of 2 quarters · filed 2026-02-04 | $16.50M 10-K · filed 2026-02-04 | |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-28 | $5.00M 10-Q · filed 2025-10-28 | ||
| 2024-06-30 | $5.00M 10-Q · filed 2025-08-01 | |||
| 2023-12-31 | $3.80M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-04 | $54.90M derived: sum of 2 quarters · filed 2026-02-04 | $54.90M 10-K · filed 2026-02-04 | |
| 2023-09-30 | $51.10M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-31 | $51.10M 10-Q · filed 2024-10-31 | ||
| 2023-06-30 | $0.00 10-Q · filed 2024-08-01 | |||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-05 | $0.00 derived: sum of 2 quarters · filed 2025-02-05 | $230.30M 10-K · filed 2025-02-05 | |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $230.30M 10-Q · filed 2023-11-02 | ||
| 2022-06-30 | $230.30M 10-Q · filed 2022-08-03 | |||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-05 | $0.00 derived: sum of 2 quarters · filed 2024-02-05 | $0.00 10-K · filed 2024-02-05 | |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $0.00 10-Q · filed 2022-11-03 | ||
| 2021-06-30 | $0.00 10-Q · filed 2022-08-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 |